36.31

0.14% -0.06

Pharvaris Nv (PHVS)

Overview News Price History Discussions Forecast

Pharvaris Nv stock is traded at $36.31, with a volume of 423.26K. It is down -0.14% in the last 24 hours and up +0.14% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Previous Close:

$36.37

Open:

$36.33

24h Volume:

423.26K

Relative Volume:

0.66

Market Cap:

$2.55B

Revenue:

Net Income/Loss:

$-195.21M

P/E Ratio:

-11.43

EPS:

-3.1763

Net Cash Flow:

$-176.19M

1W Performance:

-6.54%

1M Performance:

+0.14%

6M Performance:

+39.69%

1Y Performance:

+43.22%

1-Day Range:

$35.50

$36.88

1-Week Range:

$35.50

$40.00

52-Week Range:

$20.65

$43.25

Pharvaris Nv Stock (PHVS) Company Profile

Name

Pharvaris Nv

Sector

Healthcare (1073)

Industry

Biotechnology (594)

Phone

Address

Employee

129

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, MRNA, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHVS Pharvaris Nv	36.34	2.67B	0	-195.21M	-176.19M	-3.1763
VRTX Vertex Pharmaceuticals Inc	511.31	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	794.15	80.46B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	174.79	57.48B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	998.81	61.58B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	365.60	39.20B	5.76B	514.49M	1.10B	4.4813

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-09-26	Initiated	RBC Capital Mkts	Outperform
Oct-15-25	Initiated	H.C. Wainwright	Buy
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-11-25	Initiated	Guggenheim	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris Nv Stock (PHVS) Latest News

Sep 12, 2026

(PHVS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Sep 12, 2026

Sep 11, 2026

Pharvaris Soars on Breakthrough Trial Win and Lofty Targets - TipRanks

Sep 11, 2026

Sep 10, 2026

Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance

Sep 10, 2026